Talari HR, Azad ZJ, Hamidian Y, Samimi M, Gilasi HR, Ebrahimi Afshar F, Ostadmohammadi V, Asemi Z (2019) Effects of carnitine administration on carotid intima-media thickness and inflammatory factors in patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial
BMI of 30 or above, or BMI of 27 or above with an obesity-related health condition Health conditions such as high blood pressure, insulin resistance, sleep apnea, or elevated cholesterol History of unsuccessful attempts with diet, exercise, or commercial weight loss programs Willingness to combine medication with nutrition, movement, and lifestyle changes Not currently pregnant or planning pregnancy in the near term No contraindications to GLP-1 therapy based on health history and provider review Candidacy for compounded semaglutide and compounded tirzepatide is reviewed individually
It is not for human consumption, therapeutic use, or veterinary applications
CJC 1295 and Ipamorelin offers the best solution as it offers performance-enhancing effects to athletes
Zepbound phase 3 trials
BRLG, MFC, DBC, HJD, and JCGG are employees of Procter & Gamble and are named as co-inventors on patents relevant to this work
